Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays.

Eckstein M, Sailer V, Nielsen BS, Wittenberg T, Wiesmann V, Lieb V, Nolte E, Hartmann A, Kristiansen G, Wernert N, Wullich B, Taubert H, Wach S; German Prostate Cancer Consortium (DPKK).

Lab Invest. 2019 Jun 11. doi: 10.1038/s41374-019-0251-8. [Epub ahead of print]

PMID:
31186527
2.

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma.

Kahlmeyer A, Stöhr CG, Hartmann A, Goebell PJ, Wullich B, Wach S, Taubert H, Erlmeier F.

J Clin Med. 2019 May 24;8(5). pii: E743. doi: 10.3390/jcm8050743.

3.

[The 16th DPKK annual conference "Urology meets Pathology"].

Taubert H, Becker C, Füssel S, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2019 Jun;58(6):686-689. doi: 10.1007/s00120-019-0941-2. German. No abstract available.

PMID:
31069452
4.

sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro.

Tsaur I, Hüsch T, Jüngel E, Schneider F, Schneider M, Haferkamp A, Thomas C, Lieb V, Wach S, Taubert H, Chun FK, Blaheta RA.

Urol Oncol. 2019 Jun;37(6):355.e1-355.e9. doi: 10.1016/j.urolonc.2019.03.001. Epub 2019 Apr 18.

PMID:
31005422
5.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
6.

Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo.

Wach S, Brandl M, Borchardt H, Weigelt K, Lukat S, Nolte E, Al-Janabi O, Hart M, Grässer F, Giedl J, Jung R, Stöhr R, Hartmann A, Lieb V, Höbel S, Peters A, Stäubert C, Wullich B, Taubert H, Aigner A.

Mol Ther Nucleic Acids. 2019 Jun 7;16:272-283. doi: 10.1016/j.omtn.2019.02.020. Epub 2019 Feb 27.

7.

Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients.

Rot S, Kaune T, Taubert H, Greither T, Kotrba J, Güttler A, Wichmann H, Bilkenroth U, Wienke A, Al-Nawas B, Bache M, Vordermark D, Wickenhauser C, Bethmann D, Eckert AW, Kappler M.

BMC Cancer. 2019 Feb 15;19(1):155. doi: 10.1186/s12885-019-5327-8.

8.

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients.

Stöhr CG, Steffens S, Polifka I, Jung R, Kahlmeyer A, Ivanyi P, Weber F, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2019 Feb 11;9(1):1741. doi: 10.1038/s41598-018-38254-3.

9.

Role of androgen receptor splice variants, their clinical relevance and treatment options.

Wach S, Taubert H, Cronauer M.

World J Urol. 2019 Jan 19. doi: 10.1007/s00345-018-02619-0. [Epub ahead of print]

PMID:
30659302
10.

Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.

Eckert AW, Horter S, Bethmann D, Kotrba J, Kaune T, Rot S, Bache M, Bilkenroth U, Reich W, Greither T, Wickenhauser C, Vordermark D, Taubert H, Kappler M.

Int J Mol Sci. 2019 Jan 16;20(2). pii: E375. doi: 10.3390/ijms20020375.

11.

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.

Eckstein M, Jung R, Weigelt K, Sikic D, Stöhr R, Geppert C, Agaimy A, Lieb V, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2018 Dec 6;8(1):17693. doi: 10.1038/s41598-018-35637-4.

12.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
13.

Low HIF-1α and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently.

Rot S, Taubert H, Bache M, Greither T, Würl P, Holzhausen HJ, Eckert AW, Vordermark D, Kappler M.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3842. doi: 10.3390/ijms19123842.

14.

Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival.

Greither T, Fischer K, Theil G, Marcou M, Holzhausen HJ, Weigelt K, Serrero G, Hicks D, Yue B, Fornara P, Wullich B, Taubert H, Wach S, Lieb V.

Cancer Manag Res. 2018 Oct 5;10:4173-4180. doi: 10.2147/CMAR.S172069. eCollection 2018.

15.

Cytotoxicity of AMANTADIG - a semisynthetic digitoxigenin derivative - alone and in combination with docetaxel in human hormone-refractory prostate cancer cells and its effect on Na+/K+-ATPase inhibition.

Silva IT, Munkert J, Nolte E, Schneider NFZ, Rocha SC, Ramos ACP, Kreis W, Braga FC, de Pádua RM, Taranto AG, Cortes V, Barbosa LA, Wach S, Taubert H, Simões CMO.

Biomed Pharmacother. 2018 Nov;107:464-474. doi: 10.1016/j.biopha.2018.08.028. Epub 2018 Aug 11.

PMID:
30107342
16.

[15th annual conference of the DPKK : Molecular analysis in diagnosis and treatment].

Taubert H, Becker C, Borkowetz A, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2018 Aug;57(8):966-968. doi: 10.1007/s00120-018-0710-7. German. No abstract available.

PMID:
29934648
17.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

18.

P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients.

Kappler M, Kotrba J, Kaune T, Bache M, Rot S, Bethmann D, Wichmann H, Güttler A, Bilkenroth U, Horter S, Gallwitz L, Kessler J, Greither T, Taubert H, Eckert AW, Vordermark D.

Clin Transl Radiat Oncol. 2017 Jun 27;5:6-11. doi: 10.1016/j.ctro.2017.05.002. eCollection 2017 Aug.

19.

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients.

Lieb V, Weigelt K, Scheinost L, Fischer K, Greither T, Marcou M, Theil G, Klocker H, Holzhausen HJ, Lai X, Vera J, Ekici AB, Horninger W, Fornara P, Wullich B, Taubert H, Wach S.

Oncotarget. 2017 Dec 30;9(12):10402-10416. doi: 10.18632/oncotarget.23781. eCollection 2018 Feb 13.

20.

Elevated HERV-K Expression in Soft Tissue Sarcoma Is Associated with Worsened Relapse-Free Survival.

Giebler M, Staege MS, Blauschmidt S, Ohm LI, Kraus M, Würl P, Taubert H, Greither T.

Front Microbiol. 2018 Feb 13;9:211. doi: 10.3389/fmicb.2018.00211. eCollection 2018.

21.

Diagnostic potential of major and trace elements in the serum of bladder cancer patients.

Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, Wullich B, Taubert H, Chaudhri A.

J Trace Elem Med Biol. 2018 Mar;46:150-155. doi: 10.1016/j.jtemb.2017.12.010. Epub 2017 Dec 28.

PMID:
29413105
22.

[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].

Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV.

Aktuelle Urol. 2018 Jan 25. doi: 10.1055/s-0043-115426. [Epub ahead of print] German.

PMID:
29370587
23.

CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients.

Greither T, Wedler A, Rot S, Keßler J, Kehlen A, Holzhausen HJ, Bache M, Würl P, Taubert H, Kappler M.

Int J Mol Sci. 2017 Dec 7;18(12). pii: E2648. doi: 10.3390/ijms18122648.

24.

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma.

Bellut J, Bertz S, Nolte E, Stöhr C, Polifka I, Lieb V, Herrmann E, Jung R, Hartmann A, Wullich B, Taubert H, Wach S.

Sci Rep. 2017 Nov 27;7(1):16424. doi: 10.1038/s41598-017-16144-4.

25.

Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma.

Greither T, Vorwerk F, Kappler M, Bache M, Taubert H, Kuhnt T, Hey J, Eckert AW.

Oncol Rep. 2017 Aug;38(2):1268-1275. doi: 10.3892/or.2017.5764. Epub 2017 Jun 28.

PMID:
28677748
26.

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.

PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.

27.

Production of the Cytotoxic Cardenolide Glucoevatromonoside by Semisynthesis and Biotransformation of Evatromonoside by a Digitalis lanata Cell Culture.

Munkert J, Santiago Franco M, Nolte E, Thaís Silva I, Oliveira Castilho R, Melo Ottoni F, Schneider NFZ, Oliveira MC, Taubert H, Bauer W, Andrade SF, Alves RJ, Simões CMO, Braga FC, Kreis W, de Pádua RM.

Planta Med. 2017 Aug;83(12-13):1035-1043. doi: 10.1055/s-0043-109557. Epub 2017 May 9.

PMID:
28486743
28.

Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.

Goebel S, Kehlen A, Bluemke K, Altermann W, Schlaf G, Fischer K, Fornara P, Wullich B, Wach S, Taubert H.

Cancer Immunol Immunother. 2017 May;66(5):565-571. doi: 10.1007/s00262-017-1957-3. Epub 2017 Feb 9.

PMID:
28184970
29.

Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes.

Szczyrba J, Jung V, Beitzinger M, Nolte E, Wach S, Hart M, Sapich S, Wiesehöfer M, Taubert H, Wennemuth G, Eichner N, Stempfl T, Wullich B, Meister G, Grässer FA.

Prostate Cancer. 2017;2017:4893921. doi: 10.1155/2017/4893921. Epub 2017 Jan 5.

30.

miR-199a-5p regulates HIF-1α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome.

Keßler J, Rot S, Bache M, Kappler M, Würl P, Vordermark D, Taubert H, Greither T.

Oncol Lett. 2016 Dec;12(6):5281-5288. doi: 10.3892/ol.2016.5320. Epub 2016 Oct 26.

31.

A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.

Nolte E, Wach S, Silva IT, Lukat S, Ekici AB, Munkert J, Müller-Uri F, Kreis W, Oliveira Simões CM, Vera J, Wullich B, Taubert H, Lai X.

Oncotarget. 2017 Feb 14;8(7):11676-11691. doi: 10.18632/oncotarget.14644.

32.

Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis.

Ghoochani A, Hatipoglu Majernik G, Sehm T, Wach S, Buchfelder M, Taubert H, Eyupoglu IY, Savaskan N.

Oncotarget. 2016 Jun 21;7(25):38306-38318. doi: 10.18632/oncotarget.9439.

33.

HLA-E expression and its clinical relevance in human renal cell carcinoma.

Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A.

Oncotarget. 2016 Oct 11;7(41):67360-67372. doi: 10.18632/oncotarget.11744.

34.

Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, Keck B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):339-44. doi: 10.1007/s00428-016-1986-x. Epub 2016 Jul 8.

PMID:
27392930
35.

How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause FS, Merten R, Ott O, Fietkau R, Wullich B, Keck B.

Urol Int. 2017;98(3):262-267. doi: 10.1159/000447361. Epub 2016 Jul 5.

PMID:
27376673
36.

Multiple cryptic species of sympatric generalists within the avian blood parasite Haemoproteus majoris.

Nilsson E, Taubert H, Hellgren O, Huang X, Palinauskas V, Markovets MY, Valkiūnas G, Bensch S.

J Evol Biol. 2016 Sep;29(9):1812-26. doi: 10.1111/jeb.12911. Epub 2016 Jun 27.

37.

[Annual meeting of the German Prostate Cancer Consortium: Updates to circulating tumor cells, "liquid biopsy" and the role of the androgen receptor].

Taubert H, Becker C, Füssel S, Seitz G, Thelen P, Wullich B.

Urologe A. 2016 May;55(5):661-2. doi: 10.1007/s00120-016-0105-6. German. No abstract available.

PMID:
27130182
38.

Normoxic accumulation of HIF1α is associated with glutaminolysis.

Kappler M, Pabst U, Rot S, Taubert H, Wichmann H, Schubert J, Bache M, Weinholdt C, Immel UD, Grosse I, Vordermark D, Eckert AW.

Clin Oral Investig. 2017 Jan;21(1):211-224. doi: 10.1007/s00784-016-1780-9. Epub 2016 Mar 9.

PMID:
26955835
39.

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.

Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S.

Oncogenesis. 2016 Feb 29;5:e205. doi: 10.1038/oncsis.2016.15.

40.

MiRNA-21 Expression Decreases from Primary Tumors to Liver Metastases in Colorectal Carcinoma.

Feiersinger F, Nolte E, Wach S, Rau TT, Vassos N, Geppert C, Konrad A, Merkel S, Taubert H, Stürzl M, Croner RS.

PLoS One. 2016 Feb 4;11(2):e0148580. doi: 10.1371/journal.pone.0148580. eCollection 2016.

41.

Considering genetic characteristics in German Holstein breeding programs.

Segelke D, Täubert H, Reinhardt F, Thaller G.

J Dairy Sci. 2016 Jan;99(1):458-67. doi: 10.3168/jds.2015-9764. Epub 2015 Nov 18.

42.

The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines.

Nolte E, Sobel A, Wach S, Hertlein H, Ebert N, Müller-Uri F, Slany R, Taubert H, Wullich B, Kreis W.

Anticancer Res. 2015 Oct;35(10):5271-5.

PMID:
26408686
43.

Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma.

Jasinski-Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Hüttelmaier S, Spath V, Wartenberg R, Legal W, Taubert H, Wach S, Wullich B, Hartmann A, Seliger B.

Oncoimmunology. 2015 Mar 2;4(6):e1008805. eCollection 2015 Jun.

44.

Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Goebell PJ, Schick S, Olbert P, Huber J, Wullich B, Keck B.

Anticancer Res. 2015 Jul;35(7):4277-81.

PMID:
26124390
45.

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.

Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A.

Mol Med. 2015 May 13;21:371-80. doi: 10.2119/molmed.2014.00250.

46.

Frequency of TERT Promoter Mutations in Prostate Cancer.

Stoehr R, Taubert H, Zinnall U, Giedl J, Gaisa NT, Burger M, Ruemmele P, Hurst CD, Knowles MA, Wullich B, Hartmann A.

Pathobiology. 2015;82(2):53-7. doi: 10.1159/000381903. Epub 2015 May 21.

47.

mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma.

Bache M, Rot S, Keßler J, Güttler A, Wichmann H, Greither T, Wach S, Taubert H, Söling A, Bilkenroth U, Kappler M, Vordermark D.

Oncol Rep. 2015 Jun;33(6):3155-61. doi: 10.3892/or.2015.3932. Epub 2015 Apr 27.

PMID:
25963717
48.

The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.

Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, Theil G, Nolte E, Holzhausen HJ, Stöhr R, Huppert V, Hartmann A, Fornara P, Wullich B, Taubert H.

Int J Cancer. 2015 Sep 15;137(6):1406-16. doi: 10.1002/ijc.29505. Epub 2015 Mar 18.

49.

Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.

Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R.

J Cancer Res Clin Oncol. 2015 Oct;141(10):1779-90. doi: 10.1007/s00432-015-1942-1. Epub 2015 Mar 4.

PMID:
25732201
50.

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Fuessel S, Erdmann K, Taubert H, Lohse-Fischer A, Zastrow S, Meinhardt M, Bluemke K, Hofbauer L, Fornara P, Wullich B, Baretton G, Magdolen V, Wirth MP, Kotzsch M.

BMC Cancer. 2014 Dec 18;14:974. doi: 10.1186/1471-2407-14-974.

Supplemental Content

Loading ...
Support Center